Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2019
July 10 2019 - 8:00AM
Business Wire
- Company’s novel approach to addressing
Alzheimer’s to be featured in two Developing Topics abstracts at
AAIC
Cortexyme, Inc. (Nasdaq: CRTX), today announced that its work to
pioneer a novel disease-modifying therapeutic approach to treat a
key underlying cause of Alzheimer’s and other degenerative diseases
will be discussed in two research abstracts at the Alzheimer’s
Association International Conference® 2019 (AAIC®). The conference,
which is the largest international meeting dedicated to advancing
dementia science, will be held July 14-18, 2019 in Los Angeles.
In a Developing Topics poster (P4-663), researchers will detail
the rationale for and design of the GAIN trial, the recently
initiated Phase 2/3 study of Cortexyme’s lead gingipain inhibitor,
COR388, in subjects with mild to moderate Alzheimer’s disease (AD).
The GAIN trial is based on growing evidence that points to a key
role for Porphyromonas gingivalis, the bacterium most commonly
associated with chronic periodontal disease, in the development of
AD, based on the identification of the bacteria in the brain of AD
patients and its ability to cause neurodegeneration, inflammation,
and other pathology associated with Alzheimer’s in animal
models.
“We’re in a critical moment for Alzheimer’s drug development,
and patients deserve new approaches driven by solid science,” said
Casey Lynch, Cortexyme’s chief executive officer, chair, and
co-founder. “The researchers at Cortexyme, along with our academic
and industry collaborators, look forward to the opportunity to
share the latest updates on our work to evaluate the gingipain
hypothesis, which represents a wholly new, potentially
disease-modifying approach to a disease that affects millions of
patients and their families globally.”
A second Developing Topics poster (P4-542) will examine the
utility of a speech-based digital biomarker for tracking disease
progression and treatment response to COR388. This tool, developed
by Winterlight Labs, was deployed in Cortexyme’s Phase 1b clinical
trial of COR388 and is also being used as an exploratory endpoint
in the GAIN trial.
The schedule of Cortexyme-related presentations expected at the
meeting is as follows:
[Abstract P4-663]: “Initiation of the Phase 2/3 GAIN trial of
COR388, a novel bacterial virulence factor inhibitor for the
treatment of Alzheimer’s Disease (AD) based on Phase 1 a/b safety,
PK, biomarker and efficacy data” Mike Detke, M.D., Ph.D., et
al. Session: Developing Topics – Poster Presentations Poster
presented Wed., July 17, 2019, 9:30am - 4:15pm, South Hall GH and
discussed during AAIC press briefing earlier on that same day
[Abstract P4-542] “Utility of speech-based digital biomarkers
for evaluating disease progression in clinical trials of
Alzheimer's disease” William Simpson, Ph.D., et al. Session:
Developing Topics – Poster Presentations Poster presented Wed.,
July 17, 2019, 9:30am - 4:15pm, South Hall GH
About Cortexyme, Inc.
Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical
company pioneering a novel disease-modifying therapeutic approach
to treat a key underlying cause of Alzheimer’s disease and other
degenerative diseases. Cortexyme is targeting a specific,
infectious pathogen found in the brain of Alzheimer’s patients and
tied to neurodegeneration and neuroinflammation in animal models.
The company’s lead investigational medicine, COR388, is the subject
of the GAIN trial, an ongoing Phase 2/3 clinical study in patients
with mild to moderate Alzheimer’s disease. More information about
the trial can be found at www.GAINtrial.com. To learn more about
Cortexyme, visit www.cortexyme.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. Factors that could cause
actual results to differ include, but are not limited to, the risks
and uncertainties described in the section titled “Risk Factors” in
the final prospectus related to Cortexyme’s initial public offering
filed with the Securities and Exchange Commission on May 9, 2019
and Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on June 12, 2019. Forward-looking statements
contained in this press release are made as of this date, and
Cortexyme undertakes no duty to update such information except as
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190710005435/en/
Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415)
994-0040
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024